個人簡介
胡卓偉，1982年畢業(yè)于湖南醫(yī)科大學(xué)（現(xiàn)中南大學(xué)湘雅醫(yī)學(xué)院)碩士研究班,隨后留校從事臨床工作。1985年到美國加州大學(xué)作博士后訪問學(xué)者。1986年進(jìn)入斯坦福大學(xué)繼續(xù)臨床藥理博士后研究。1992年獲斯坦福大學(xué)分子細(xì)胞生理學(xué)專業(yè)博士學(xué)位。從1992年起在斯坦福大學(xué)醫(yī)學(xué)院工作期間歷任研究科學(xué)家、高級科學(xué)家、高級副研究員和高級研究員，并從1985年起擔(dān)任美國輝瑞制藥公司臨床前研究顧問多年�，F(xiàn)為中國醫(yī)學(xué)科學(xué)院藥物研究所研究研究員，博士生導(dǎo)師，中國醫(yī)學(xué)科學(xué)院協(xié)和醫(yī)科大學(xué)特聘教授、中南大學(xué)客座教授。國家人事部2003年度高層次留學(xué)人才回國資助人員。
目前主要從事的研究領(lǐng)域
我們的研究領(lǐng)域包括免疫生物學(xué)和免疫藥理、心血管生物學(xué)和心血管藥理、分子細(xì)胞生物學(xué)和蛋白質(zhì)組學(xué)、受體和信號傳導(dǎo)通道的調(diào)節(jié)機(jī)制。本研究室的長期研究目標(biāo)是研究許多嚴(yán)重威脅公眾健康和生命的疾病機(jī)制，在深入了解疾病發(fā)生發(fā)展機(jī)制的基礎(chǔ)上，開發(fā)能夠預(yù)防和治療這些疾病的藥物。
免疫反應(yīng)包括先天性免疫反應(yīng)和獲得性免疫反應(yīng)。先天免疫系統(tǒng)是人體對內(nèi)源性和外源性致病原產(chǎn)生免疫應(yīng)答和急性炎癥反應(yīng)的第一道防線。先天免疫系統(tǒng)主要由補(bǔ)體、多形核細(xì)胞、天然殺傷細(xì)胞(NK)樹突狀細(xì)胞(DC)等組成。獲得免疫系統(tǒng)主要由白細(xì)胞和淋巴細(xì)胞介導(dǎo)，包括體液免疫反應(yīng)和細(xì)胞免疫反應(yīng)。體液免疫反應(yīng)由B淋巴細(xì)胞分泌的抗體介導(dǎo)，細(xì)胞免疫由T淋巴細(xì)胞分泌的細(xì)胞因子介導(dǎo)。T細(xì)胞包括細(xì)胞毒Ｔ(Tc)、幫助Ｔ(Th)和調(diào)節(jié)Ｔ(Treg)細(xì)胞。先天性免疫系統(tǒng)的幾個成分通過不同的機(jī)制促使抗原提呈細(xì)胞特別是樹突狀細(xì)胞(DC)成熟，決定了獲得性免疫系統(tǒng)中B淋巴細(xì)胞發(fā)育和T淋巴細(xì)胞分泌的Th1、Th2細(xì)胞因子的極化方向。獲得性免疫反應(yīng)的Th1或Th2細(xì)胞因子極化方向改變是許多疾病例如組織纖維化和組織重構(gòu)的關(guān)鍵因素。目前,我們的研究方向包括具有抗原呈遞功能的DC細(xì)胞和NK細(xì)胞之間的相互作用；DC細(xì)胞和T細(xì)胞之間的相互作用特別是DC細(xì)胞發(fā)育成熟及活性是如何決定Th1,Th2和調(diào)節(jié)性T細(xì)胞(Treg)發(fā)育方向。
組織纖維化是多種嚴(yán)重威脅人類健康疾病的基本病理改變，累及人體幾乎所有器官和系統(tǒng)，是許多疾病致殘、致死的主要原因。目前沒有有效治療組織纖維化疾病的藥物。我們正在使用不同的組織纖維化動物模型和細(xì)胞模型，從免疫學(xué)角度研究組織纖維化發(fā)生和發(fā)展的病原生物學(xué)和病理生理學(xué)機(jī)制。我們的目的是在深入理解纖維增生性疾病分子機(jī)制基礎(chǔ)上，開發(fā)抗組織纖維化藥物。因此，本課題具有重要的理論和實際意義。
心血管疾病嚴(yán)重危害人類的健康。全世界許多國家心血管疾病都是威脅人類健康的“第一殺手”，每年有一千七百萬人（1/3全球死亡率）死于心血管疾病。我們的研究方向包括研究心血管疾病的病原學(xué)和病理機(jī)制；心血管疾病發(fā)病過程中的信號傳導(dǎo)機(jī)制，特別是G蛋白偶合受體和生長因子受體介導(dǎo)的細(xì)胞生物學(xué)反應(yīng)中的信號傳導(dǎo)機(jī)制和真核基因表達(dá)調(diào)控機(jī)制。在此基礎(chǔ)上，發(fā)現(xiàn)治療心血管疾病的新藥靶，開發(fā)治療心血管疾病藥物。
目前出版的教科書和專著
1. Hu ZW: Drugs and Cardiovascular System. in Clive Page et al.(eds.) Integrated Pharmacology: Basic Science to Therapeutics. The Second Edition, 2002, Mosby, London.
2. Hu ZW: 新藥發(fā)現(xiàn)和篩選的藥靶選擇. 劉剛等編著：尋找新藥中的組合化學(xué)（Combinatorial Chemistry for Drug Lead Discovery and Optimization）. 北京：科學(xué)出版社, 2003
3. Hu ZW and Lin RZ: Drugs and the Blood. in Clive Page et al.(eds.) Integrated Pharmacology: Basic Science to Therapeutics. 1997, Mosby, London.
4. Lin RZ and Hu ZW: Therapeutics of Hematological Disorders. in Carruthers SG et al.(eds.) Melmon & Morrelliu2019s Clinical Pharmacology: The principles and practical application of therapeutics. The Fourth Edition, 2000, McGraw-Hill, New York.
5. Hu ZW and Hoffman BB: Nuclear run-on assays for measurement of adrenergic receptor transcription rate. in Machida (ed.) Adrenergic Receptor Protocols. The Methods in Molecular Biology (series editor: John Walker), 1999, Humana Press, Totowa, New Jersey.
目前發(fā)表的代表性論文
[1]. Hu ZW, Kerb R, Shi XY, Wei-Lavery T, Hoffman BB: Angiotensin II increases expression of cyclooxygenase-2: implications for the function of vascular smooth muscle cells. J Pharmacol Exp Ther. 2002, 303:563-573.
[2]. Hoffman BB and Hu ZW: Alpha(1)-adrenoceptors (alpha(1)-AR) and vascular smooth muscle cell growth. Prostate Suppl. 2000, 9:29-33.
[3]. Hu ZW, Shi XY, Lin ZR, and Hoffman BB: Alpha1-Adrenergic Receptor Stimulation of Mitogenesis in Human VSMCs: Role of Tyrosine Protein Kinases and Calcium in Activation of MAP Kinase. J. Pharmacol. Exper. Ther. 1999, 290:28-37
[4]. Chen J, Lin RZ, Hu Z-W, and Hoffman BB: Alpha1-Adrenergic receptor activation of c-fos expression in transfected rat-1 fibroblasts: role of Ca2+. J. Pharmacol. Exper Ther. 1999, 289:1376-1384.
[5]. Hu ZW, Shi XY, Lin ZR, and Hoffman BB: Differential Signaling Pathways Mediate Alpha1 AR Subtype Activation of Phosphatidylinositol 3-Kinase in transfected NIH3T3 Cells. Role of Gbeta/gama subunits. Mol. Endocrol. 1999, 13:3-14
[6]. Hu ZW, Shi XY, and Hoffman BB: Doxazosin inhibits proliferation and migration of human vascular smooth muscle cells. J. Cardiovasc. Pharmacol. 1998, 31:833-839
[7]. Lin RZ, Chen J, Hu ZW, and Hoffman BB: Phosphorylation of the cAMP response element binding protein and activation of transcription by alpha1 adrenergic receptors. J. Biol. Chem. 1998, 273:30033-30038
[8]. Lin RZ, Hu ZW, Chin JH, and Hoffman BB: Heat shock activates c-Src tyrosine kinase and phosphatidylinositol 3-kinase in NIH3T3 fibroblasts. J. Biol. Chem. 1997, 272:31196-31202
[9]. Okazaki M, Hu ZW, Fujinaga M, and Hoffman BB: Alpha1 adrenergic receptor activation of protooncogene expression in arterial smooth muscle: regulation by NO and vascular injury. Rec. Sign. Trans. 1996, 6:165-178
[10]. Hu ZW, Shi XY, and Hoffman BB: Insulin and insulin-like growth factor I differentially induce alpha1 adrenergic receptor subtype expression in cultured vascular smooth muscle cells. J. Clin. Invest. 1996, 98:1826-1834.
[11]. Hu ZW, Shi XY, Lin RZ, and Hoffman BB: Alpha1 adrenergic receptors activate phosphatidylinositol 3-kinase in human vascular smooth muscle cells: roles in mitogenesis. J. Biol.Chem. 1996,271:9887-92
[12]. Chin JH, Okazaki M, Hu ZW, Miller JW, and Hoffman BB: Stimulation of alpha1 ARs induces transcription activation of heat shock protein 70 gene by enhancement of heat shock protein transcription factor in rat aortic smooth muscle. J. Clin. Invest. 1996, 97:2316-2323
[13]. Chin JH, Okazaki M, Frazier JS, Hu ZW, and Hoffman BB: Impaired cAMP-mediated gene expression and decreased cAMP response element binding protein in senescent fibroblasts. Am. J. Physiol. 1996, 271:C362-C371
[14]. Thomas JM, Frazier JS, Hu ZW, and Hoffman BB: Phosphorylation of cAMP response element binding protein and induction of c-fos gene expression upon withdrawal from chronic treatment with carbachol in NG108-15 cells. Mol. Pharmacol. 1995, 48:593-600
[15]. Fujinaga M, Hu ZW, Okazaki M, Baden JM and Hoffman BB: Expression of mRNA for alpha1 ARs subtypes at the beginning of neurulation in rat embryos. Teratology 1995, 9:601-6
[16]. Hu ZW, Shi XY, Okazaki M and Hoffman BB: Angiotensin II induces transcription and expression of α1-adrenergic receptors in cultured rat vascular smooth muscle cells. Am. J. Physiol. 1995, 268:H1006-H1014
[17]. Okazaki M, Hu ZW, Fujinaga M, and Hoffman BB: Alpha1 adrenergic receptor-induced c-fos gene expression in rat aorta and cultured vascular smooth muscle cells. J. Clin. Invest. 1994, 94:210-218.
[18]. Hu ZW and Hoffman BB: Cycloheximide activates transcription of alpha1B AR gene expression in DDT1 MF-2 smooth muscle cells. Mol. Pharmacol. 1993, 44:1105-1112
[19]. Hu ZW, Shi XY, Sakaue M, and Hoffman BB: prolonged activation of protein kinase C by phorbol esters induces transcription and expression of the alpha1B-AR gene in DDT1 MF2 cells. J. Biol.Chem.1993,268:3390-95
[20]. Hu ZW, Miller J W, and Hoffman BB: Induction of enhanced release of endothelium-derived relaxing factor following prolonged exposure to alpha adrenergic agonists: role in desensitization of smooth muscle contraction. J. Cardiovasc Pharmacol. 1994, 23:337-343
[21]. Hu ZW, Arzha S, and Hoffman BB: Prolonged activation of alpha 1 adrenergic receptors resulted in down-regulation of protein kinase C in rat aortic smooth muscle. J. Cardiovasc. Pharmacol. 1992, 20:982-989
[22]. Hu ZW, Honda K, Murad F, and Hoffman BB: Prolonged exposure to catecholamines enhances sensitivity of SM relaxation induced by sodium nitroprusside and atrioptin. J. Pharmacol. Exp.Ther. 1992, 260:756-61
[23]. Hu ZW, Billingham M, Tuck M, and Hoffman BB: Captopril Improves hypertension and cardiomyopathy in rats with pheochromocytoma. Hypertension 1990; 15:210-215
[24]. Hu ZW. Effect of nifedipine on platelet function. Chung Hua Hsin Hsueh Kuan Ping Tsa Chih 1986, 14:145-146
[25]. Hu ZW. Abnormalities of myocardial lipid metabolism and advances of drug intervention in acute myocardial ischemia. Sheng Li Ko Hsueh Chin Chan 1984, 15:35-40
足球運動員
另有足球運動員胡卓偉。
